Inflammatory Bowel Disease Treatment Market, By Type (Crohns Disease and Ulcerative Colitis), By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5565
|
Published Date
July 2026
|
Pages
333
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Inflammatory Bowel Disease Treatment Market size was valued at US$ 24,306.2 Million in 2025, expanding at a CAGR of 6.1% from 2026 to 2033.
The inflammatory bowel disease (IBD) treatment market is undergoing significant transformation, shifting from a landscape dominated by traditional anti-TNF therapies toward a broader range of advanced treatments with diverse mechanisms of action. For many years, Humira (adalimumab) was a leading therapy in the IBD treatment space; however, recent years have witnessed the emergence of newer therapeutic classes, including IL-23 inhibitors, JAK inhibitors, S1P receptor modulators, and next-generation integrin-targeted therapies. This evolution reflects a broader shift in immunology toward more targeted treatment approaches designed to improve disease control and address varying patient responses.
IBD represents a significant long-term healthcare burden due to its chronic and lifelong nature, requiring continuous disease management rather than short-term intervention. In the United States, IBD affects more than 0.7% of the population, with incidence often increasing during early adulthood and creating a sustained need for maintenance therapies. The expanding treatment landscape, rising focus on personalized medicine, and continued innovation in immune-targeted therapies have positioned inflammatory bowel disease as one of the most competitive and rapidly evolving areas within the immunology market.
Inflammatory Bowel Disease Treatment Market- Market Dynamics
Increasing Early Use of Biologic Treatments Fueling Market Expansion
The management approach for inflammatory bowel disease (IBD) is shifting as physicians increasingly adopt biologic therapies earlier in the disease course rather than reserving them only for patients who fail conventional treatments. This change is driven by growing clinical evidence demonstrating that early biologic intervention can help reduce intestinal damage, achieve deeper remission, and improve long-term disease outcomes. The treat-to-target approach, which focuses on achieving measurable disease control and preventing disease progression, has become an important strategy in IBD management. Since 2023, the U.S. Food and Drug Administration (FDA) has expanded approvals for therapies such as Skyrizi, Omvoh, and Rinvoq, providing gastroenterologists with additional targeted treatment options for patients with Crohn’s disease and ulcerative colitis.
As more advanced therapies become available across both major forms of IBD, physicians are gaining greater confidence in using biologics earlier and selecting treatments based on individual patient characteristics and disease severity. According to the Crohn’s & Colitis Foundation, approximately 3.1 million adults in the United States are living with inflammatory bowel disease, representing a significant patient population that may benefit from earlier access to advanced therapies. This increasing adoption of biologics, combined with continued innovation in targeted immune therapies, is expected to support sustained growth in the global inflammatory bowel disease treatment market.
Inflammatory Bowel Disease Treatment Market- Segmentation Analysis:
The Global Inflammatory Bowel Disease Treatment Market is segmented on the basis of Type, Drug Class, Route of Administration, Distribution Channel, and Region.
By type, Crohn’s disease remains a challenging condition to treat due to its ability to affect multiple areas of the gastrointestinal tract and cause serious complications, including fistulas and strictures. These complications often require long-term disease management and may involve the use of biologic therapies to achieve and maintain control. According to the U.S. Centers for Disease Control and Prevention (CDC), a study among Medicare beneficiaries showed that the prevalence of Crohn’s disease increased at an annual percentage change (APC) of 3.4% between 2001 and 2018. Ulcerative colitis is generally more prevalent than Crohn’s disease in several countries. Population-based data published by the National Institutes of Health (NIH) reported prevalence rates of 334 cases per 100,000 population for ulcerative colitis and 306 cases per 100,000 population for Crohn’s disease in Australia.
By drug class, the initial treatment approach for Crohn’s disease and ulcerative colitis typically includes aminosalicylates and corticosteroids. According to recommendations from the American Gastroenterological Association (AGA) and the European Crohn’s and Colitis Organisation (ECCO), corticosteroids are primarily used for inducing remission rather than for long-term maintenance therapy. This has accelerated the adoption of steroid-sparing treatments, particularly biologic therapies. The second-line treatment segment represents a significant portion of the market and includes advanced therapies such as IL inhibitors, TNF inhibitors, JAK inhibitors, anti-integrin agents, and S1P receptor modulators. This segment has experienced substantial innovation and increasing competition due to the introduction of targeted therapies. According to IQVIA, biologics account for more than 60% of prescription drug spending in inflammatory bowel disease across major developed markets. Clinical evidence, including the SONIC trial, demonstrated that combination therapy achieved corticosteroid-free remission in approximately 57% of Crohn’s disease patients compared with 44% of patients receiving infliximab monotherapy, supporting the continued use of combination approaches in selected high-risk populations.
Inflammatory Bowel Disease Treatment Market- Geographical Insights
North America holds the leading position in the global inflammatory bowel disease (IBD) treatment market, supported by the high prevalence of IBD, a well-established healthcare infrastructure, a large network of gastroenterology specialists, and rapid adoption of advanced biologic therapies. The United States serves as a major hub for IBD treatment innovation, with several novel biologics and targeted therapies receiving regulatory approval and entering clinical practice ahead of many other regions. According to the Crohn’s & Colitis Foundation, approximately 2.4 million people in the United States are living with IBD, including nearly 1 million individuals with ulcerative colitis and around 1 million with Crohn’s disease, with thousands of new cases diagnosed each year. The region’s strong clinical research ecosystem and early access to therapies such as Skyrizi, Omvoh, Velsipity, and Entyvio continue to reinforce North America’s dominance in the IBD treatment landscape.
Europe is expected to witness significant growth in the IBD treatment market, driven by the rising disease burden, improving access to advanced therapies, and increasing adoption of biologic and targeted treatments. Several European countries, including the United Kingdom, Denmark, and Norway, report some of the highest prevalence rates of ulcerative colitis globally, creating substantial demand for effective long-term treatment options. According to epidemiological studies published in the Journal of Crohn’s and Colitis, ulcerative colitis prevalence is estimated to be approximately 570 cases per 100,000 population in the United Kingdom, 523 cases per 100,000 in Denmark, and 500 cases per 100,000 in Norway. In addition, expanding healthcare coverage, improved diagnostic capabilities, and greater availability of advanced biologic therapies are supporting market expansion across the region.
Inflammatory Bowel Disease Treatment Market- Competitive Landscape:
The competitive landscape of the **inflammatory bowel disease (IBD) treatment market** is largely shaped by leading pharmaceutical companies focusing on biologic therapies, targeted immunomodulators, and expanding treatment portfolios. AbbVie Inc. has strengthened its position in the immunology market through its diversified IBD portfolio, including therapies with multiple mechanisms of action such as TNF inhibition through Humira, IL-23 inhibition through Skyrizi, and JAK inhibition through Rinvoq. This broad therapeutic approach enables physicians to select treatments based on disease severity, patient characteristics, and treatment response. In 2024, Skyrizi received approval for the treatment of moderately to severely active ulcerative colitis, further expanding AbbVie’s presence across major IBD indications.
Takeda Pharmaceutical Company Limited remains another key player in the IBD treatment market through its leading biologic therapy Entyvio. The company continues to strengthen its position by expanding Entyvio’s availability across formulations and indications for both ulcerative colitis and Crohn’s disease. However, Takeda faces increasing competitive pressure from newer targeted therapies, including IL-23 inhibitors and JAK inhibitors such as Skyrizi and Rinvoq, which offer alternative mechanisms of action and treatment options for patients.
Recent Developments
- In January 2026, Boehringer Ingelheim entered into a global partnership agreement with Sincere Pharmaceutical Group for the IBD drug candidate **SIM0709**. The collaboration strengthens Boehringer Ingelheim’s pipeline in inflammatory diseases and supports the development of new treatment options for IBD patients.
- In 2024, the U.S. Food and Drug Administration approved AbbVie’s Skyrizi for the treatment of moderately to severely active ulcerative colitis based on results from the INSPIRE induction and COMMAND maintenance studies. The approval expanded Skyrizi’s role as an IL-23-specific therapy across both major IBD indications, following its earlier use in Crohn’s disease. The therapy also received approval in Japan during the same year, further expanding its global availability.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Biogen
- Novartis AG
- Lilly
- UCB S.A.
- CELLTRION INC.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc
- Boehringer Ingelheim
- Bausch Health Companies Inc.
- Ferring Pharmaceuticals
- Gilead Sciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- Others
GLOBALINFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Crohn’s Disease
- Ulcerative Colitis
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Aminosalicylates
- Corticosteroids
- TNF Inhibitors
- IL Inhibitors
- JAK Inhibitors
- Anti-Integrin
- S1P Receptor Modulators
- Others
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Oral
- Injectable
- Rectal
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Inflammatory Bowel Disease Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Inflammatory Bowel Disease Treatment Market Snippet by Type
2.1.2. Inflammatory Bowel Disease Treatment Market Snippet by Drug Class
2.1.3. Inflammatory Bowel Disease Treatment Market Snippet by Route of Administration
2.1.4. Inflammatory Bowel Disease Treatment Market Snippet by Distribution Channel
2.1.5. Inflammatory Bowel Disease Treatment Market Snippet by Country
2.1.6. Inflammatory Bowel Disease Treatment Market Snippet by Region
2.2. Competitive Insights
3. Inflammatory Bowel Disease Treatment Key Market Trends
3.1. Inflammatory Bowel Disease Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Inflammatory Bowel Disease Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Inflammatory Bowel Disease Treatment Market Opportunities
3.4. Inflammatory Bowel Disease Treatment Market Future Trends
4. Inflammatory Bowel Disease Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Inflammatory Bowel Disease Treatment Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Inflammatory Bowel Disease Treatment Market Landscape
6.1. Inflammatory Bowel Disease Treatment Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Inflammatory Bowel Disease Treatment Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
7.1.2. Crohn’s Disease
7.1.3. Ulcerative Colitis
8. Inflammatory Bowel Disease Treatment Market – By Drug Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
8.1.2. Aminosalicylates
8.1.3. Corticosteroids
8.1.4. TNF Inhibitors
8.1.5. IL Inhibitors
8.1.6. JAK Inhibitors
8.1.7. Anti-Integrin
8.1.8. S1P Receptor Modulators
8.1.9. Others
9. Inflammatory Bowel Disease Treatment Market – By Route of Administration
9.1. Overview
9.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
9.1.2. Oral
9.1.3. Injectable
9.1.4. Rectal
10. Inflammatory Bowel Disease Treatment Market – By Distribution Channel
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
10.1.2. Hospital Pharmacy
10.1.3. Retail Pharmacy
10.1.4. Online Pharmacy
11. Inflammatory Bowel Disease Treatment Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Inflammatory Bowel Disease Treatment Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.17. Denmark
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.17.4. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.17.5. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.17.6. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.18. Rest of Europe
11.3.18.1. Overview
11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.18.3. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.16. Taiwan
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.16.4. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.16.5. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.16.6. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.17. Vietnam
11.4.17.1. Overview
11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.17.3. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.17.4. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.17.5. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.17.6. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.18. Rest of APAC
11.4.18.1. Overview
11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.18.3. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.18.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Inflammatory Bowel Disease Treatment Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.14. Iran
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.14.4. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.14.5. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.14.6. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.15. Qatar
11.6.15.1. Overview
11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.15.3. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.15.4. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.15.5. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.15.6. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.16. Rest of MEA
11.6.16.1. Overview
11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.16.3. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
11.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.16.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
11.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Inflammatory Bowel Disease Treatment Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. AbbVie Inc.
12.2.2. Takeda Pharmaceutical Company Limited
12.2.3. Pfizer Inc.
12.2.4. Biogen
12.2.5. Novartis AG
12.2.6. Lilly
12.2.7. UCB S.A.
12.2.8. CELLTRION INC.
12.2.9. Merck & Co., Inc.
12.2.10. Johnson & Johnson Services, Inc
12.2.11. Boehringer Ingelheim
12.2.12. Bausch Health Companies Inc.
12.2.13. Ferring Pharmaceuticals
12.2.14. Gilead Sciences, Inc.
12.2.15. Teva Pharmaceutical Industries Ltd.
12.2.16. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Biogen
- Novartis AG
- Lilly
- UCB S.A.
- CELLTRION INC.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc
- Boehringer Ingelheim
- Bausch Health Companies Inc.
- Ferring Pharmaceuticals
- Gilead Sciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- Others
GLOBALINFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Crohn’s Disease
- Ulcerative Colitis
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Aminosalicylates
- Corticosteroids
- TNF Inhibitors
- IL Inhibitors
- JAK Inhibitors
- Anti-Integrin
- S1P Receptor Modulators
- Others
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Oral
- Injectable
- Rectal
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
